Exelixis, Inc. (EXEL): A Bull Case Theory

We came across a bullish thesis on Exelixis, Inc. on Investing With Purpose’s. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $37.42 as of August 29th. EXEL’s trailing and forward P/E were 17.99 and 17.33 respectively according to Yahoo Finance.

microscope, health

Likoper/Shutterstock.com

Exelixis (EXEL) is a rare oncology biotech that combines profitability with growth optionality, driven by its flagship CABOMETYX franchise. CABOMETYX, approved...